Catheter Precision (VTAK) Net Income towards Common Stockholders (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$3.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 24.82% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$12.0 million, a 19.26% increase from a year earlier, with the FY2025 full-year figure at -$17.2 million, up 21.18% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.0 million, down from -$370000.0 in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for VTAK reached as high as -$6967.0 in Q1 2022 and fell as low as -$67.4 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$7.4 million across 5 years, with a median of -$2.7 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders jumped 99.81% in 2022 and plunged 966887.23% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$18.4 million in 2022, then jumped by 97.29% to -$499000.0 in 2023, then tumbled by 398.4% to -$2.5 million in 2024, then surged by 85.12% to -$370000.0 in 2025, then sank by 721.89% to -$3.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$3.0 million in Q1 2026, -$370000.0 in Q4 2025, and -$2.2 million in Q3 2025.